Thymalin
Research OnlyAlso known as: Thymulin, Thymic Factor, Timalin, Thymarin
A thymic peptide complex developed in Russia and used clinically in the former Soviet Union for immunomodulation. Derived from calf thymus extract, it contains multiple peptides claimed to restore immune function. Approved in Russia since the 1970s but not recognized by Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western replication.
Research Statistics
Russian bioregulator (Khavinson lab); bovine thymic extract approved in Russia. Research primarily from Russian institutes with some human observational studies. No independent Western clinical trials. Thymic bioregulation mechanism is proposed through peptide bioregulation theory.
Research Dossier
Overview
What is Thymalin and what does the research say?
Mechanism of Action
The proposed mechanisms of Thymalin are based on Russian clinical studies and preclinical research. Western mechanistic validation remains limited.
How It Works (Simplified)
Thymalin acts as a thymic hormone replacement, supporting immune function through multiple pathways:
Promotes hematopoietic stem cell differentiation into mature T-lymphocytes by modulating CD44, CD117, and CD28 expression markers.
Suppresses pro-inflammatory cytokines (IL-1B, IL-6, TNF-a) while enhancing anti-inflammatory responses via NF-kB pathway inhibition.
Short peptides (EW, KE, EDP) bind to specific DNA sequences and histone proteins, influencing expression of immune-related genes.
Enhances natural killer cell activity and number, contributing to innate immune surveillance and anti-tumor responses.
Scientific Pathways
T-Cell Maturation Pathway (Immune Restoration)
Thymalin -> HSC CD44/CD117 downregulation -> CD28 upregulation -> Mature T-lymphocytes
|
Enhanced cellular immunityAnti-Inflammatory Pathway (Cytokine Storm Prevention)
Thymalin -> NF-kB/IKK inhibition -> Reduced IL-1B, IL-6, TNF-a -> Anti-inflammatory effectKey Research: Khavinson VKh et al. (Russia, 2020) demonstrated HSC differentiation markers in vitro. PMID:33237528
Important Limitations
- Extract composition varies between batches (not a defined single compound)
- Most studies from single Russian research group (Khavinson laboratory)
- Trial methodology may not meet current Western standards
- Exact active peptide responsible for effects not definitively identified
- No FDA, EMA, or other Western regulatory approval
- Bovine-derived product carries theoretical contamination concerns
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on Russian clinical protocols: Initial immune marker changes may begin. In-vitro studies show T-cell differentiation marker changes within 24-48 hours. Clinical response timing in humans varies.
Russian clinical reports suggest lymphocyte count improvements may become detectable. COVID-19 study showed NK-cell normalization within this timeframe. Inflammatory marker changes observed in preclinical models.
Continued immune function optimization expected based on Russian treatment protocols. Standard Russian clinical courses typically last 5-10 days with effects claimed to persist for months.
Long-term Russian studies claim sustained immunomodulatory effects. The 6-8 year mortality study suggested persistent benefits. However, human pharmacokinetics and optimal treatment intervals are not well characterized by Western standards.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Thymalin product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Thymalin with other peptides. Based on published research and mechanistic considerations.
Thymosin-Alpha-1
SynergisticBoth target immune restoration through thymic pathways. Thymosin Alpha-1 is a defined single peptide while Thymalin is a complex. Theoretical synergy for immune reconstitution but no clinical combination studies exist.
Thymogen
SynergisticThymogen (EW dipeptide) is a synthetic derivative believed to be one of Thymalin's active components. May produce overlapping effects; combining may be redundant.
BPC-157
CompatibleNon-overlapping mechanisms. BPC-157 focuses on tissue repair while Thymalin modulates immune function. No known contraindications; theoretical complementary benefits.
LL-37
CompatibleLL-37's antimicrobial and immunomodulatory properties may complement Thymalin's T-cell enhancing effects. No interaction studies available.
Epithalon
CompatibleBoth are Khavinson peptides with proposed geroprotective effects through different mechanisms. Epithalon targets telomerase while Thymalin targets immune function. Often combined in Russian anti-aging protocols.
Semax
CompatibleDifferent primary targets (immune vs cognitive). No known interactions. Both have Russian regulatory approval for distinct indications.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Thymalin
Thymalin Calculators
Related Peptides
Alpha-Defensins
HNP-1, HNP-2, HNP-3 +5 more
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val, Lysine-Proline-Valine, alpha-MSH(11-13) +1 more
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Kristagen
EDG, Glu-Asp-Gly, Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB, Lactoferricin B, LfcinB +1 more
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin, hCAP18, Human Cationic Antimicrobial Peptide 18 +3 more
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080, RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.
Related Content
Thymosin Alpha-1
Immune · moderate evidence
Thymogen
Immune · moderate evidence
Thymulin
Immune · moderate evidence
What is Thymalin?
An introduction to thymalin, a thymic peptide extract studie...
Bronchogen vs Thymalin
View side-by-side analysis
Cardiogen vs Thymalin
View side-by-side analysis